MarketCap
Facebook
X
Telegram
Nkarta Interest Expense | NKTX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Nkarta
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.42 M | 87 K | 42 K | -470 K | -16 K | -3 K | 18 K | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.42 M | -470 K | 297 K |
Quarterly Interest Expense Nkarta
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 206 K | 222 K | 206 K | 256 K | 1.72 M | 239 K | 205 K | 94 K | -3 K | -2 K | -2 K | -25 K | 33 K | 1 K | 33 K | -489 K | 17 K | 3 K | -1 K | -2 K | -6 K | -5 K | -2 K | 146 K | -153 K | 4 K | - | - | 35 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.72 M | -489 K | 101 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Sesen Bio
SESN
|
296 K | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
-408 K | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
3.27 M | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-3 K | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-16 K | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
290 K | - | - | $ 13 M | USA |
 |
Brickell Biotech
BBI
|
5 K | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-77 K | - | - | $ 8.42 M | USA |
 |
Merus N.V.
MRUS
|
1.06 M | - | - | $ 5.78 B |  Niderland |
 |
Annexon
ANNX
|
57 K | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
2.89 B | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
-207 K | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
99.9 M | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
268 M | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
1.25 M | $ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Exelixis
EXEL
|
-198 K | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
-375 K | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
-1 M | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
5.2 M | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
2.69 K | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
789 K | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
83.8 M | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
7.21 B | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
2 K | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-132 K | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
2.89 M | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
680 K | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-357 K | $ 84.95 | 0.13 % | $ 7.99 B | USA |
|
TFF Pharmaceuticals
TFFP
|
14.5 K | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
21.8 M | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
2.37 M | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.73 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
1.6 M | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-4.81 M | $ 1.09 | 6.37 % | $ 95 M | USA |